In a report released on November 10, Brian Skorney from Robert W. Baird maintained a Hold rating on VistaGen Therapeutics (VTGN – Research Report), with a price target of $0.25. The company’s shares closed last Friday at $0.16.
Skorney covers the Healthcare sector, focusing on stocks such as Biogen, Intercept Pharma, and Eiger Biopharmaceuticals. According to TipRanks, Skorney has an average return of -7.0% and a 43.28% success rate on recommended stocks.
VistaGen Therapeutics has an analyst consensus of Hold, with a price target consensus of $0.25.
See Insiders’ Hot Stocks on TipRanks >>
Based on VistaGen Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $310.1 thousand and a GAAP net loss of $19.78 million. In comparison, last year the company earned a revenue of $354.1 thousand and had a GAAP net loss of $7.74 million
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VTGN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
